RXRX RECURSION PHARMACEUTICALS, ...

Nasdaq recursion.com


$ 4.19 $ 0.32 (8.31 %)    

Friday, 21-Nov-2025 15:55:33 EST
QQQ $ 589.65 $ 4.40 (0.75 %)
DIA $ 462.56 $ 5.05 (1.1 %)
SPY $ 658.52 $ 6.50 (1 %)
TLT $ 89.50 $ 0.27 (0.3 %)
GLD $ 373.77 $ -0.58 (-0.15 %)
$ 4.17
$ 3.91
$ 4.18 x 2,995
$ 4.19 x 25,812
$ 3.85 - $ 4.25
$ 3.79 - $ 12.36
33,334,109
na
2.17B
$ 2.60
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 recursion-pharmaceuticals-q3-eps-036-misses-031-estimate-sales-5175m-miss-16983m-estimate

Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly losses of $(0.36) per share which missed the analyst consensus estim...

 costco-amd-recursion-pharmaceuticals-cipher-mining-and-snowflake-why-these-5-stocks-are-on-investors-radars-today

On Wednesday, major U.S. indices closed mixed, with the Nasdaq rising 1.1% to 23,043.38 and the S&P 500 slipping nearly 0.6...

 whats-going-on-with-recursion-pharmaceuticals-stock-on-wednesday

Recursion Pharmaceuticals' stock rises on heavy trading volume, with investors eyeing its AI-designed cancer drug REC-3565 ...

 jim-cramer-says-this-financial-stock-is-a-total-spec-likes-dutch-bros

On CNBC's “Mad Money Lightning Round,” Jim Cramer said he likes Dutch Bros (NYSE: BROS). He recommended buying some now and...

 needham-reiterates-buy-on-recursion-pharmaceuticals-maintains-8-price-target

Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and maintains $8 price target.

 recursion-pharmaceuticals-reports-wider-than-expected-q2-loss-beats-revenue-estimates

Recursion reported second-quarter revenue of $19.22 million, beating analyst estimates of $16.23 million, according to Benzinga...

 palantir-nvidia--tempus-ai-could-be-pharma-etf-darlings-that-dont-make-pills

Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still...

 how-palantir-tempus-nvidia-backed-recursion-are-disrupting-big-pharma

AI-native players like Palantir, Tempus, and Recursion are disrupting drug discovery and attracting investors, while Big Pharma...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION